264 related articles for article (PubMed ID: 36102777)
21. Self-Reported Quality of Life and Symptom Burden in Ambulatory Patients With Multiple Myeloma on Disease-Modifying Treatment.
Kiely F; Cran A; Finnerty D; O'Brien T
Am J Hosp Palliat Care; 2017 Aug; 34(7):671-676. PubMed ID: 27141015
[TBL] [Abstract][Full Text] [Related]
22. Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial.
Weisel K; Dimopoulos M; Song KW; Moreau P; Palumbo A; Belch A; Schey S; Sonneveld P; Sternas L; Yu X; Amatya R; Gibson CJ; Zaki M; Jacques C; San Miguel J
Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):519-30. PubMed ID: 26149712
[TBL] [Abstract][Full Text] [Related]
23. Health-related quality of life and use of medication with anticholinergic activity in patients with multiple myeloma.
de Lima MSR; de Pádua CAM; de Miranda Drummond PL; Silveira LP; Malta JS; Dos Santos RMM; Reis AMM
Support Care Cancer; 2023 Jun; 31(7):379. PubMed ID: 37278732
[TBL] [Abstract][Full Text] [Related]
24. The association between sociodemographic factors, frailty, and health-related quality of life in older inpatients: a cross-sectional study.
Li Q; Han B; Chen X
Qual Life Res; 2020 Dec; 29(12):3233-3241. PubMed ID: 32564292
[TBL] [Abstract][Full Text] [Related]
25. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT
Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497
[TBL] [Abstract][Full Text] [Related]
26. Individualized dynamic frailty-tailored therapy (DynaFiT) in elderly patients with newly diagnosed multiple myeloma: a prospective study.
Zhang Y; Liang X; Xu W; Yi X; Hu R; Ma X; Yan Y; Zhang N; Wang J; Sun X; Zhu Y; Tian M; Lan M; Long M; Dai Y; Jin F
J Hematol Oncol; 2024 Jun; 17(1):48. PubMed ID: 38915117
[TBL] [Abstract][Full Text] [Related]
27. Prevalence of geriatric impairments and frailty categorization among real-world patients with multiple myeloma: a prospective cohort study (MFRAIL).
Haider I; Leong DP; Louzada M; McCurdy A; Pond GR; Cameron R; Aljama M; Visram A; Wildes TM; Mian H
Leuk Lymphoma; 2024 Apr; ():1-8. PubMed ID: 38625039
[TBL] [Abstract][Full Text] [Related]
28. Integrating Touchscreen-Based Geriatric Assessment and Frailty Screening for Adults With Multiple Myeloma to Drive Personalized Treatment Decisions.
Nathwani N; Kurtin SE; Lipe B; Mohile SG; Catamero DD; Wujcik D; Birchard K; Davis A; Dudley W; Stricker CT; Wildes TM
JCO Oncol Pract; 2020 Jan; 16(1):e92-e99. PubMed ID: 31765266
[TBL] [Abstract][Full Text] [Related]
29. Transplant eligibility in elderly multiple myeloma patients: Prospective external validation of the international myeloma working group frailty score and comparison with clinical judgment and other comorbidity scores in unselected patients aged 65-75 years.
Belotti A; Ribolla R; Cancelli V; Crippa C; Bianchetti N; Ferrari S; Bottelli C; Cattaneo C; Tucci A; De La Fuente Barrigon C; Rossi G
Am J Hematol; 2020 Jul; 95(7):759-765. PubMed ID: 32242970
[TBL] [Abstract][Full Text] [Related]
30. Health-related quality of life in Croatian general population and multiple myeloma patients assessed by the EORTC QLQ-C30 and EORTC QLQ-MY20 questionnaires.
Ficko SL; Pejsa V; Zadnik V
Radiol Oncol; 2019 Sep; 53(3):337-347. PubMed ID: 31553711
[TBL] [Abstract][Full Text] [Related]
31. Comparison of Frailty Scores in Newly Diagnosed Patients with Multiple Myeloma: A Review.
Mian H; Brouwers M; Kouroukis CT; Wildes TM
J Frailty Aging; 2019; 8(4):215-221. PubMed ID: 31637409
[TBL] [Abstract][Full Text] [Related]
32. The importance of frailty assessment in multiple myeloma: a position statement from the Myeloma Scientific Advisory Group to Myeloma Australia.
Sim S; Kalff A; Tuch G; Mollee P; Ho PJ; Harrison S; Gibbs S; Prince HM; Spencer A; Joshua D; Lee C; Ling S; Murphy N; Szabo F; Szer J; Weber N; Ward C; Talaulikar D; Zannettino A; Quach H
Intern Med J; 2023 May; 53(5):819-824. PubMed ID: 36880355
[TBL] [Abstract][Full Text] [Related]
33. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Attal M; Richardson PG; Rajkumar SV; San-Miguel J; Beksac M; Spicka I; Leleu X; Schjesvold F; Moreau P; Dimopoulos MA; Huang JS; Minarik J; Cavo M; Prince HM; Macé S; Corzo KP; Campana F; Le-Guennec S; Dubin F; Anderson KC;
Lancet; 2019 Dec; 394(10214):2096-2107. PubMed ID: 31735560
[TBL] [Abstract][Full Text] [Related]
34. Impact of atrial fibrillation on frailty and functionality in older adults.
Koca M; Yavuz BB; Tuna Doğrul R; Çalışkan H; Şengül Ayçiçek G; Özsürekçi C; Balcı C; Eşme M; Ünsal P; Halil M; Cankurtaran M
Ir J Med Sci; 2020 Aug; 189(3):917-924. PubMed ID: 31997061
[TBL] [Abstract][Full Text] [Related]
35. Reliability and Validity of an Iranian Version of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for Patients with Multiple Myeloma: the EORTC QLQ-MY20.
Ahmadzadeh A; Yekaninejad MS; Saffari M; Pakpour AH; Aaronson NK
Asian Pac J Cancer Prev; 2016; 17(1):255-9. PubMed ID: 26838220
[TBL] [Abstract][Full Text] [Related]
36. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial.
Yan Z; Cao J; Cheng H; Qiao J; Zhang H; Wang Y; Shi M; Lan J; Fei X; Jin L; Jing G; Sang W; Zhu F; Chen W; Wu Q; Yao Y; Wang G; Zhao J; Zheng J; Li Z; Xu K
Lancet Haematol; 2019 Oct; 6(10):e521-e529. PubMed ID: 31378662
[TBL] [Abstract][Full Text] [Related]
37. Health-Related Quality of Life of Patients With Multiple Myeloma Treated in Routine Clinical Practice in France.
Despiégel N; Touboul C; Flinois A; Saba G; Suzan F; Gonzalez-McQuire S; Bonnetain F
Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):e13-e28. PubMed ID: 30292736
[TBL] [Abstract][Full Text] [Related]
38. Use of the European Organisation for Research and Treatment of Cancer multiple myeloma module (EORTC QLQ-MY20): a review of the literature 25 years after development.
Forde K; Cocks K; Wells JR; McMillan I; Kyriakou C;
Blood Cancer J; 2023 May; 13(1):79. PubMed ID: 37193682
[TBL] [Abstract][Full Text] [Related]
39. Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study.
Cella D; McKendrick J; Kudlac A; Palumbo A; Oukessou A; Vij R; Zyczynski T; Davis C
Ann Hematol; 2018 Dec; 97(12):2455-2463. PubMed ID: 30178193
[TBL] [Abstract][Full Text] [Related]
40. Geriatric Assessment and Frailty Scores Predict Mortality in Myeloma: Systematic Review and Meta-analysis.
Salazar AS; Recinos LM; Mian HS; Stoll C; Simon LE; Sekhon S; Colditz GA; Wildes TM
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):488-496.e6. PubMed ID: 31133527
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
